Lamassu Biotech leverages collaboration between academia and industry to identify novel therapeutics with high potential for clinical impact. Focusing on therapies with strong scientific rationale and preclinical efficacy data, we build the best scientific case, examining the mechanism, exploring additional models and indications, and identifying the most promising path forward for regulatory approval and clinical impact.
We capitalize on our expertise in early translational research to bring products to Phase I/II and partner with clinical and commercial development specialists to advance clinical trials through the approval pipeline. Our innovative model ensures that early development efforts bring products to definitive clinical testing as efficiently as possible to benefit patients, while safeguarding safety and investments.
Learn More
PARTNERS
PHASE 1/2
SA53 CLINICAL EVALUATION
THERE ARE SEVERAL POTENTIALLY ATTRACTIVE ONCOLOGY INDICATIONS FOR SA53 CLINICAL DEVELOPMENT, THE SELECTION OF WHICH WILL BE BASED ON THE INITIAL PHASE 1 AND RESULTS AND CLINICAL AND COMMERCIAL OPPORTUNITIES.
Learn More